Logo

ZVRA

Zevra Therapeutics, Inc.

ZVRA

Zevra Therapeutics, Inc. • NASDAQ
$8.43 ▼ -1.98% (-0.17)
Market Cap $474.57 M
52w High $13.16
52w Low $6.19
Dividend Yield 0%
P/E 17.94
Volume 567.80K
Outstanding Shares 56.29M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $26.063M ▲ $20.367M ▼ $-1.41M ▼ -5.41% ▼ $-0.01 ▼ $1.466M ▼
Q2-2025 $25.881M ▲ $84.541M ▲ $74.707M ▲ 288.656% ▲ $1.364 ▲ $80.566M ▲
Q1-2025 $20.401M ▲ $24.418M ▼ $-3.099M ▲ -15.19% ▲ $-0.057 ▲ $1.701M ▲
Q4-2024 $12.043M ▲ $26.093M ▼ $-35.739M ▼ -296.762% ▲ $-0.67 ▲ $-16.526M ▲
Q3-2024 $3.695M $28.698M $-33.225M -899.188% $-0.69 $-29.296M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $199.509M ▼ $270.116M ▲ $136.951M ▼ $133.165M ▲
Q2-2025 $202.611M ▲ $256.277M ▲ $139.047M ▲ $117.23M ▲
Q1-2025 $62.631M ▼ $172.708M ▼ $131.685M ▼ $41.023M ▲
Q4-2024 $69.496M ▼ $178.127M ▼ $138.461M ▲ $39.666M ▼
Q3-2024 $89.376M $191.551M $121.781M $69.77M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-544K ▼ $4.709M ▲ $-4.576M ▼ $6.53M ▲ $6.727M ▼ $4.155M ▲
Q2-2025 $74.707M ▲ $-3.601M ▲ $11.934M ▲ $1.381M ▼ $10.372M ▲ $-3.814M ▲
Q1-2025 $-3.099M ▲ $-8.222M ▲ $10.542M ▲ $1.607M ▲ $3.555M ▲ $-8.321M ▲
Q4-2024 $-35.739M ▼ $-16.25M ▲ $-5.471M ▲ $796K ▼ $-20.254M ▼ $-16.25M ▲
Q3-2024 $-33.225M $-18.141M $-31.354M $64.765M $14.779M $-18.141M

Revenue by Products

Product Q1-2024Q2-2024
License
License
 $0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Zevra is still very much in the “build” phase financially. Revenue remains very small, while expenses tied to R&D, operations, and commercialization are much larger. Losses have persisted for several years and recently have widened again after a brief period of improvement. Overall, this is a classic early-stage biotech profile: limited sales so far, meaning the business is not yet covering its cost base and remains dependent on external funding and future product uptake.

Balance Sheet

Balance Sheet The balance sheet shows a modest asset base with a meaningful portion in cash, but that cash has been trending down from earlier peaks. Debt has been introduced or increased over time, which adds some financial obligations that did not exist in the past. Shareholders’ equity has moved from negative to positive, which is a sign of past repair, but more recently it has started to shrink. In simple terms, Zevra has some financial cushion, but not an excess one, and its room for error is limited if losses continue at the current pace.

Cash Flow

Cash Flow Cash flow reflects the income statement story: the company is consistently using cash rather than generating it. Operating cash flow has been negative in most recent years, indicating that day‑to‑day operations are not self-funding. Free cash flow mirrors this pattern, as capital spending is minimal; the main driver of cash use is operating losses, not heavy investment in equipment. This means the company’s future cash position depends heavily on its ability to grow product revenues, control spending, and access capital when needed.

Competitive Edge

Competitive Edge Zevra operates in a niche where small patient populations, high unmet need, and complex care pathways shape the competitive landscape. Its approved rare disease products, MIPLYFFA and OLPRUVA, benefit from regulatory designations and potential periods of market exclusivity, which can limit direct competition. The company also gains strength from deep relationships with rare disease communities and specialists. However, the narrow markets, dependence on reimbursement, and the need to build commercial reach from a relatively small base mean its position, while differentiated, is not yet firmly entrenched and will depend on real-world adoption and clinical outcomes.

Innovation and R&D

Innovation and R&D The core of Zevra’s story is its focus on rare and ultra‑rare diseases with serious unmet needs. Its lead assets illustrate different innovation angles: a first‑in‑class mechanism for Niemann‑Pick type C, a more patient‑friendly formulation for urea cycle disorders, and a late‑stage program for a severe connective tissue disorder. The company has also advanced a sleep‑disorder candidate to a late stage of development. Strategically, Zevra has shifted away from early discovery toward late‑stage and commercial opportunities, aiming to be more selective and capital‑efficient. This approach can reduce scientific risk per program but concentrates the company’s future on a small number of high‑stakes assets.

Summary

Zevra is a classic rare‑disease biotech in transition from pure development to early commercialization. On the positive side, it has approved products with orphan protections, a focused pipeline addressing serious conditions, and a strategy centered on capital efficiency and targeted acquisitions. On the risk side, revenues are still very small relative to expenses, losses are material, and cash is being drawn down, which keeps financing and execution risks front and center. The company’s long‑term outcome will depend heavily on how quickly it can translate its rare‑disease portfolio—particularly MIPLYFFA, OLPRUVA, and key late‑stage programs—into sustainable, growing cash flows while maintaining enough financial flexibility to navigate setbacks.

NEWS

November 20, 2025 · 4:05 PM UTC

Zevra Therapeutics, Inc. Announces CFO Transition

Read more

November 5, 2025 · 4:05 PM UTC

Zevra Reports Third Quarter 2025 Financial Results and Corporate Update

Read more

October 29, 2025 · 7:30 AM UTC

Zevra Therapeutics to Participate in the Guggenheim Healthcare Innovation Conference

Read more

October 27, 2025 · 7:30 AM UTC

Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call

Read more

October 6, 2025 · 5:51 PM UTC

Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Read more